Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 trial of peripheral blood lymphocytes transduced with a murine T-cell receptor recognizing the G12D variant of mutated KRAS i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• Murine T-cell receptor-engineered peripheral blood lymphocytes targeting G12D KRAS (HLA-A*11:01)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Cancer, Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED